Information from XVIVO Perfusion´s Nomination Committee
XVIVO Perfusion AB’s Nomination Committee proposes that the Annual General Meeting to be held on April 27, 2018 re-elects the sitting board members Gösta Johannesson, Erik von Schenck, Camilla Öberg and Folke Nilsson. Fredrik Mattsson and Semmy Rülf have declined re-election.
Gösta Johannesson is proposed to be elected as the chairman of the board. The Nomination Committee further proposes Yvonne Mårtensson and Alan Raffensperger as new board members.
Yvonne Mårtensson has a long and solid experience from the Med tech and life science industry, most recently from the role as CEO for CellaVision AB during 1998-2014. Yvonne Mårtensson also has experience as a board member of life science companies. Yvonne Mårtensson holds a M.Sc. (Tech.) in Engineering and Management from Linköping Institute of Technology.
Alan Raffensperger has a long and solid experience from the Med tech and life science industry. Alan is currently CEO for Inceptua SA, and before that the role as COO for SOBI (Swedish Orphan Biovitrum AB) during 2012-2017. Before that, during 2010-2012, Alan Raffensperger was CEO for Benechill Inc. Alan Raffensperger holds a MBA from George Washington University and a B.Sc. in Health Services Management from University of Maryland Baltimore.
The Nomination Committee’s other proposals will be published in the notice to the Annual General Meeting.
For the 2018 Annual General Meeting, the Nomination Committee members are Henrik Blomquist (Bure Equity), Martin Lewin (Eccenovo AB) and Joachim Spetz (Swedbank Robur). The Nomination Committee has been appointed in accordance with the instruction determined at the Annual General Meeting of XVIVO Perfusion AB (publ) on May 3, 2016.
The Annual General Meeting will take place on April 27, 2018 in Gothenburg.
XVIVO Perfusion AB (publ)
Contact person:
Henrik Blomquist
Nomination Committee Chairman
Tel: +46 8 – 614 00 20
henrik.blomquist@bure.se
This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication at 3.00 am CET on March 8, 2018.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
Tags: